Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term MONOCLONAL-ANTIBODY. Found 11 abstracts

Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, Mullins S, Tsao M, Cheng JD, Zheng G. Photodynamic Molecular Beacon Triggered by Fibroblast Activation Protein on Cancer-Associated Fibroblasts for Diagnosis and Treatment of Epithelial Cancers. Journal of medicinal chemistry. 2009 Jan;52(2):358-68.   PMCID: PMC2773291
Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenbero DM. Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma. Journal of Nuclear Medicine. 2009 Mar;50(3):444-53.
Zorn KK, Tian CQ, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. The Prognostic Value of Pretreatment CA 125 in Patients With Advanced Ovarian Carcinoma A Gynecologic Oncology Group Study. Cancer. 2009 Mar;115(5):1028-35.   PMCID: PMC 2664510
Chu QS, Cianfrocca ME, Goldstein LJ, Gale M, Murray N, Loftiss J, Arya N, Koch KM, Pandite L, Fleming RA, Paul E, Rowinsky EK. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clinical Cancer Research. 2008 Jul;14(14):4484-90.
Lu ML, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, Cryns VL. Aspirin sensitizes cancer cells to TRAIL-Induced apoptosis by reducing surviving levels. Clinical Cancer Research. 2008 May;14(10):3168-76.
Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Research. 2008 Jul;68(13):5282-90.
Hecht JR, Patnaik A, Berlin J, Venook A, Malik L, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007 Sep;110(5):980-8.
Liang HH, Wu H, Giorgadze TA, Sariya D, Bellucci KS, Veerappan R, Liegl B, Acs G, Elenitsas R, Shukla S, Youngberg GA, Coogan PS, Pasha T, Zhang PJ, Xu XW. Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. American Journal of Surgical Pathology. 2007 Feb;31(2):304-10.
Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, Meropol NJ, Cheng JD. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biology & Therapy. 2007 Nov;6(11):1691-9.
Roberts JL, Lauritsen JP, Cooney M, Parrott RE, Sajaroff EO, Win CM, Keller MD, Carpenter JH, Carabana J, Krangel MS, Sarzotti M, Zhong XP, Wiest DL, Buckley RH. T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3 xi subunit of the T-cell antigen receptor complex. Blood. 2007 Apr;109(8):3198-206.
Zhou Y, Daryl C, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. Impact of single-chain fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. Journal of Molecular Biology. 2007 Aug;371(4):934-47.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term MONOCLONAL-ANTIBODY

MONOCLONAL-ANTIBODY SQUAMOUS-CELL CARCINOMA SOLID TUMORS METASTATIC COLORECTAL-CANCER XENOGRAFTS SERINE-PROTEASE IN-VIVO BREAST-CANCER COLON-CANCER PEDIATRIC VASCULAR TUMORS 1ST-LINE METASTATIC BREAST-CANCER CD3-ZETA CHAIN FIBROBLASTS CROSS-TALK POSTMENOPAUSAL WOMEN PRECLINICAL MANUFACTURE ABX-EGF CELL LUNG-CANCER progression-free survival IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY FACTOR-RECEPTOR ANTICANCER DRUGS yeast display INTRAPERITONEAL CISPLATIN CLEAVING ENZYME PHASE-III TRIAL IMMUNOHISTOCHEMICAL MARKERS trial PRE-T DURABLE RESPONSES CA-125 FUSION PROTEIN Group phase II clinical STAGE-IV MELANOMA FOLLICULAR STEM-CELLS PACLITAXEL PLUS IRINOTECAN PLUS FLUOROURACIL epithelial ovarian cancer colorectal cancer FLUOROURACIL epidermal growth factor receptor panitumumab-human monoclonal antibody-colorectal cancer TYROSINE KINASE affinity maturation RECEPTOR-INDUCED APOPTOSIS MEDIATED APOPTOSIS receptor DISPLAY LIBRARY TUMORICIDAL ACTIVITY EPIDERMAL-GROWTH-FACTOR NATURAL-KILLER-CELLS OPEN-LABEL LINKED-IMMUNOSORBENT-ASSAY adnexal carcinoma CETUXIMAB TREATMENT EPRATUZUMAB podoplanin UTERINE CERVIX LYMPHOID LYMPHATIC VESSEL DENSITY M2A ANTIGEN LEUCOVORIN ANTIGEN 5 BISPECIFIC ANTIBODY PHASE-II TRIAL I-131 TOSITUMOMAB single chain Fv antibody NONSTEROIDAL ANTIINFLAMMATORY DRUGS CYTOKERATIN TARGETED THERAPIES metastatic adenocarcinoma CARBOPLATIN RITUXIMAB MALIGNANCIES LONGITUDINAL DATA-ANALYSIS bispecific antibody non-Hodgkin lymphoma-pretargeting-radioimmunotherapy-veltuzumab-Y-90 PHAGE LIBRARIES D2-40 immunoliposome fibroblast activation protein DOSE-ESCALATION B-CELL LYMPHOMA SMALL-MOLECULE TCR ZETA-CHAIN B-CELL LYMPHOMAS LIGAND-INDUCED APOPTOSIS THERAPY AGENT CYTOCHROME-C DEVELOPMENT GROWTH-FACTOR RECEPTOR tumor fibroblasts ENDOPLASMIC-RETICULUM STAGE-III IBRITUMOMAB TIUXETAN I-131 TUMOR STROMAL FIBROBLASTS Val-boroPro NUDE-MICE LOW-GRADE BINDING-AFFINITY Gynecologic Oncology EPITHELIAL CANCERS COMBINED IMMUNE-DEFICIENCY DNA-LIGASE-IV TUMOR STROMAL MATRIX METALLOPROTEINASES CA 125 tumor marker tumor stroma CANCER HUMAN CONTROLLED-TRIAL MESOTHELIOMA INHIBITOR ALPHA-BETA COATED TUBES serine protease ALPHA-B-CRYSTALLIN 6 epidermal growth factor MALIGNANT
Last updated on Friday, August 14, 2020